Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.59 ▲ +0.07
(+4.28%)
MKT CAP: $268.7M • VOL: 5.41M
52W L $1 52W H $4
ROARABLE / RQD
D- • 42/100
PIOTROSKI
2 / 9
CABA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$172.2M | -$125.1M | -$74.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$167.9M | -$115.9M | -$67.7M |
| EBITDA (Normalized) | -$171.3M | -$123.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$131.1M | -$88.2M | -$53.5M |
| Capital Expenditures (CapEx) | $1.2M | $2.2M | — |
| Free Cash Flow (FCF) | -$132.3M | -$90.4M | -$53.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $83.0M | $164.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $112.1M | $152.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CABA.